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DBackground: This study was undertaken to examine interhospital variability in inpatient costs of coronary
artery bypass grafting (CABG).
Methods: The Nationwide Inpatient Sample was used to identify isolated CABGs performed between 2005 and
2008 in the United States. Charges for inpatient care were supplied by the data set, and hospital charge-to-cost
ratios were used to derive inpatient costs for each patient and aggregated at the hospital level.Mixed-effect linear
regression models were created to evaluate variability in costs between hospitals adjusting for 34 patient, oper-
ative, complication, and hospital-related variables.
Results: A total of 633 hospitals performed isolated CABG in 183,973 patients. In unadjusted analysis, there
was significant baseline variability in average inpatient costs of CABG between hospitals (SD, $12,130;
P<.001). This variability represented 30% of the overall unadjusted average cost of performing CABG per hos-
pital ($40,424). After risk adjustment, significant variability in average costs between hospitals persisted
(P< .001). Of the 34 additional variables included in the model, only hospital region, postoperative sepsis,
in-hospital mortality, and need for ventricular assist device, extracorporeal membrane oxygenation, permanent
pacemaker, or implantable cardioverter-defibrillator were stronger predictors of increased costs compared with
the hospital effect.
Conclusions: There is a wide variation in the cost of performing CABG in the United States. We determined that
individual hospital centers, independent of multiple patient- and outcome-specific factors, are drivers of these
differences. Comparison of hospital-specific behavior with identification of the causes of cost discrepancies
represents an opportunity for standardization of care and improvement in resource use. (J Thorac Cardiovasc
Surg 2014;147:109-16)Health care spending in the United States continues to
garner interest by multiple parties, including individual pro-
viders, hospitals, policy makers, and the public. Despite
higher costs, the quality of care provided in the United
States has not been demonstrated to be measurably superior
to that in other countries.1 This has underscored the impor-
tance of cost containment and specific strategies to reduce
health care spending.
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The Journal of Thoracic and Cathe most commonly performed procedures in the United
States. Although the heavy cost burden of coronary athero-
sclerosis on the health care system has been well studied,
there is a paucity of literature identifying systematic factors
that may contribute to variations in costs of coronary revas-
cularization. In this study, we evaluated interhospital vari-
ability in inpatient costs of CABG in the United States.PATIENTS AND METHODS
Data Source
The Nationwide Inpatient Sample was the data source used for this
study. This registry was developed as part of the Agency for Healthcare
Research and Quality Healthcare Cost and Utilization Project. It represents
a 20% stratified sample of all hospitals within the United States, with
patient-level data on approximately 8 million hospital stays per year
from 1050 hospitals.2 Because the data are publically available and deiden-
tified, the Johns Hopkins University School of Medicine Institutional
Review Board granted the study exempt status.
Inclusion and Exclusion Criteria
CABGs performed between January 1, 2005, and December 31, 2008,
were identified in the Nationwide Inpatient Sample using the International
Classification of Diseases, Ninth Revision procedure codes 36.10 to 36.19.
Inclusion criteria included adults aged 18 years or older and isolated
CABGs. Patients undergoing CABG concomitant with other major surgeryrdiovascular Surgery c Volume 147, Number 1 109
Abbreviation and Acronym
CABG ¼ coronary artery bypass grafting
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Dwere, therefore, excluded. Urgent or emergent procedures and reoperative
CABGs were included in the study population.
Primary Outcome
The primary outcome of interest was inpatient cost of CABG. Charges
for each individual patient undergoing CABG were supplied by the data
set. Cost-to-charge ratios developed by the Agency for Healthcare
Research and Quality, using Centers for Medicare and Medicaid Services
data, were then used to derive costs from hospital charges. Unique ratios
are calculated for each individual hospital. Hospital costs were used as
the primary outcome as opposed to charges because the latter reflects pric-
ing decisions related to payer policies and other factors unrelated to
resource use.
Variation in Hospital-Specific Costs
Inpatient costs of CABG were aggregated at the hospital level. To mea-
sure interhospital variability in costs, a mixed-effect linear regression
model was created using variables associated with cost of CABG in univar-
iate linear regression analysis (exploratory P<.20). All variables tested for
potential inclusion in the model were associated with CABG cost in univar-
iate analysis (P< .20) and were, therefore, included in the final model.
Patient-level variables included in the model were age, sex, primary payer
status, and Charlson comorbidity index. The Charlson comorbidity index is
a highly validated cumulative score based on patient comorbidities that is
predictive of mortality, with higher scores representing higher comorbidity
burdens. Operative variables in the model included elective versus urgent
or emergent procedure, number of coronary vessels bypassed, use of car-
diopulmonary bypass, use of the internal mammary artery, cardiac catheter-
ization during the same admission, intra-aortic balloon pump, permanent
pacemaker or implantable cardioverter-defibrillator, ventricular assist de-
vice as postcardiotomy support, extracorporeal membrane oxygenation,
coronary angioplasty during same admission, non–drug-eluting or drug-
eluting coronary stent during same admission, and redo CABG. Complica-
tions that were included in the multivariable model were as follows:
respiratory failure, pneumonia, acute renal failure, sepsis, stroke, pulmo-
nary embolism, gastrointestinal tract bleed, wound complication, hemor-
rhage, and cardiac shock or arrest. Hospital-related variables included
hospital region, teaching status, urban versus rural location, and annual
hospital CABG volume. Although the analysis was limited to isolated
CABGs, annual volume was inclusive of all CABGs, including those per-
formed concomitant to another procedure, because this would be expected
to add to the ‘‘overall experience’’ of the center in performing CABG.
Length of hospitalization, in-hospital mortality, and the year the operation
was performed were also included in the model.
These 34 covariates comprised the fixed-effect parameters in the mixed-
effect linear regression model. The random-effect parameters were the in-
dividual hospitals. The SD of the hospital effect was calculated in the
model to determine if there was significant between-center variability in
costs of CABG after adjusting for the fixed-effect parameters. All statistical
analyses were performed using STATA, version 11, software (StataCorp
LP, College Station, Tex).RESULTS
Patient and Operative Characteristics
A total of 183,973 isolated CABG patients were included
in the analysis. The mean age was 65.2  10.8 years110 The Journal of Thoracic and Cardiovascular Surg(Table 1). Most patients were males (73%), with a primary
payer status ofMedicare (52%) or private insurance (40%).
Half of the patients had a Charlson comorbidity score of 2 or
greater (47%). The most common comorbidities included
myocardial infarction (39%), diabetes mellitus (31%),
atrial fibrillation (25%), congestive heart failure (21%),
and chronic obstructive pulmonary disease (21%). A total
of 9% of the study population had chronic renal
insufficiency.
Regarding operative characteristics, most CABGs were
done on an urgent or emergent basis (55%) (Table 1). A
total of 55% of patients had a cardiac catheterization during
the same admission. Approximately half of the cases
involved a 3- or more vessel bypass. The internal mammary
artery was used as a conduit in 89%, with 73% being per-
formed on cardiopulmonary bypass. A total of 9% of
patients required an intra-aortic balloon pump. The use of
a permanent pacemaker or implantable cardioverter-
defibrillator (2%), ventricular assist device (0.1%), or
extracorporeal membrane oxygenation (0.02%) was un-
common in the study population. Coronary angioplasty
(3%) or non–drug-eluting (0.7%) or drug-eluting (0.9%)
coronary stent placement during the same admission was
also uncommon.
Hospital Characteristics
There were 633 hospitals included in the analysis. Most
patients were treated at teaching hospitals (57%) in an ur-
ban setting (97%) (Table 1). Hospital region included South
(44%), Midwest (25%), West (16%), and Northeast
(15%). The mean annual overall CABG volume was 441
 340 per year.
Mortality and Morbidity
The overall unadjusted in-hospital mortality rate was
2.2% (n¼ 3967) (Table 2). As expected, this rate was lower
in elective cases (1.5% vs 2.7%; P< .001). The mean
length of hospitalization was 9.4  7.2 days, with a median
hospitalization of 7 days (interquartile range, 6-11 days). A
major postoperative complication was observed in 36%
(n ¼ 65,538) of the study population. Individual complica-
tion rates were as follows: respiratory failure (17%;
n¼ 31,081), pneumonia (5%; n¼ 9308), acute renal failure
(9%; n ¼ 17,136), sepsis (1%; n ¼ 2351), stroke (2%;
n ¼ 3096), pulmonary embolism (0.4%; n ¼ 683), gastro-
intestinal tract bleed (0.5%; n¼ 853), wound complication
(2%; n ¼ 3094), hemorrhage (5%; n ¼ 9299), and cardiac
shock or arrest (11%; n ¼ 20,257).
Costs
The overall average inpatient cost of CABG was
$37,924  $25,374 per patient (Figure 1, A). The average
cost of a CABG at the hospital level was $40,424, with
the SD of average CABG cost between hospitals beingery c January 2014
TABLE 1. Patient, operative, and hospital characteristics of the study
population
Variable
Study population
(n ¼ 183,973) Missing data
Patient
Age, y 65.2  10.8 14 (0.008)
Male sex 133,573 (73) 14 (0.008)
Payment status 260 (0.1)
Medicare 95,287 (52)
Private insurance 73,367 (40)
Medicaid 8912 (5)
Other 6147 (3)
Charlson comorbidity score 0 (0)
0 38,420 (21)
1 59,675 (32)
>2 85,878 (47)
Comorbidities 0 (0)
Atrial fibrillation 45,959 (25)
Myocardial infarction 71,663 (39)
Congestive heart failure 39,412 (21)
Peripheral vascular disease 21,096 (11)
Cerebrovascular disease 16,072 (9)
COPD 38,493 (21)
Diabetes mellitus 56,365 (31)
Chronic renal insufficiency 15,790 (9)
Liver disease 762 (0.4)
Operative
Urgent or emergent case 100,178 (55) 306 (0.2)
No. of coronary vessels
bypassed
7750 (4)
1 26,255 (15)
2 64,201 (36)
3 57,728 (33)
>4 28,039 (16)
Use of cardiopulmonary bypass 133,748 (73) 0 (0)
Use of internal mammary
artery
163,136 (89) 0 (0)
Cardiac catheterization during
admission
101,052 (55) 0 (0)
Intra-aortic balloon pump 17,366 (9) 0 (0)
Permanent pacemaker or
implantable cardioverter-
defibrillator
3133 (2) 0 (0)
Ventricular assist device as
postcardiotomy support
203 (0.1) 0 (0)
Extracorporeal membrane
oxygenation
37 (0.02) 0 (0)
Coronary angioplasty during
admission
5601 (3) 0 (0)
Coronary stent during
admission
0 (0)
Non drug eluting 1355 (0.7)
Drug eluting 1587 (0.9)
(Continued)
TABLE 1. Continued
Variable
Study population
(n ¼ 183,973) Missing data
Hospital
Teaching hospital 104,259 (57) 0 (0)
Region 0 (0)
Northeast 27,108 (15)
Midwest 45,625 (25)
South 81,249 (44)
West 29,991 (16)
Rural location 6351 (3) 0 (0)
Annual hospital CABG
volume*
441  340 0 (0)
Data are given as mean  SD or number (percentage). COPD, Chronic obstructive
pulmonary disease; CABG, coronary artery bypass grafting. *Annual volume inclu-
sive of all CABGs performed by that hospital, including CABGs concomitant with
other procedures.
TABLE 2. Outcomes of CABG in the study population
Outcome
Study population
(n ¼ 183,973) Missing data
In-hospital mortality
Overall 3967 (2) 127 (0.07)
Elective cases 1227 (1) 55 (0.07)
Urgent or emergent cases 2735 (3) 72 (0.07)
Length of hospitalization, d 0 (0)
Mean  SD 9.4  7.2
Median (interquartile range) 7 (6-11)
Complications
Overall 65,538 (36) 0 (0)
Respiratory failure 31,081 (17) 0 (0)
Pneumonia 9308 (5) 0 (0)
Acute renal failure 17,136 (9) 0 (0)
Sepsis 2351 (1) 0 (0)
Stroke 3096 (2) 0 (0)
Pulmonary embolism 683 (0.4) 0 (0)
Gastrointestinal tract bleed 853 (0.5) 0 (0)
Wound complication 3094 (2) 0 (0)
Hemorrhage 9299 (5) 0 (0)
Cardiac shock or arrest 20,257 (11) 0 (0)
Data are given as number (percentage) unless otherwise indicated. CABG, Coronary
artery bypass grafting; SD, standard deviation.
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D$12,130 (Figure 1, B). Several significant predictors of cost
were identified in the multivariable model (Table 3). After
adjusting for multiple covariates, there persisted significantThe Journal of Thoracic and Cavariability between hospitals with respect to CABG cost
(P<.001) (Table 3 and Figure 2). The magnitude of the hos-
pital effect was greater than all variables in the model,
except for in-hospital mortality, postoperative sepsis, hospi-
tal region, ventricular assist device implantation as postcar-
diotomy support, need for extracorporeal membrane
oxygenation, and permanent pacemaker or cardioverter-
defibrillator implantation (Figure 2).
DISCUSSION
Although providing high-quality care with favorable
clinical outcomes has been the cornerstone of evaluating
surgical programs, there has been increasing emphasis onrdiovascular Surgery c Volume 147, Number 1 111
FIGURE 1. Histograms demonstrating the number of patients across the
cost spectrum (A) and the average costs of coronary artery bypass grafting
at the hospital level (B).
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Dproviding such care in an efficient manner. The inpatient
costs associated with a procedure are one measure of effi-
ciency. The costs of CABG, which remains one of the
more commonly performed operations worldwide, have
been shown to be higher in the United States than in other
countries, without necessarily a clear advantage in clinical
outcomes.3 In this study, we examined interhospital vari-
ability in costs of CABG in more than 180,000 patients in
633 hospitals in the United States.Variability in Costs of CABG Between Hospitals
The principal finding of this large-cohort analysis was
that, after accounting for multiple patient-, operative-,
complication-, and hospital-level variables, there persisted
significant variability in costs of performing CABG be-
tween hospitals. This suggests that, although different hos-
pitals may provide comparable quality of care, there is a
wide divergence in the pathways used to achieve that level
of care, with differing associated costs. These data under-
score the importance of identifying differences in practice
patterns that may contribute to cost divergence. Implemen-
tation of specific cost-effective processes of care may then
be used as a potential strategy for broader-scale cost
containment.112 The Journal of Thoracic and Cardiovascular SurgA prior analysis of 21 hospitals performing CABG in
New York State in 1992 demonstrated similar results as
our study.4 After accounting for baseline patient risk, there
persisted significant interhospital variability in costs, lead-
ing the authors to conclude that reductions in CABG cost
could be achieved by standardizing clinical practice. A
study of more than 90,000 Medicare patients undergoing
CABG in 1990 demonstrated substantial geographic vari-
ability in patient-level costs and length of hospitalization.5
Another analysis examined nearly 500,000 CABGs in the
Society of Thoracic Surgeons National Database and
demonstrated wide variability between hospitals in lengths
of hospitalization.6 Finally, a study of more than 6700
CABG patients in a statewide database found significant
differences in resource use after accounting for patient
characteristics, operative variables, and postoperative com-
plications.7 These prior reports, in conjunction with our
data, emphasize the potential utility of standardizing clin-
ical pathways as a means of reducing costs of care in
CABG.
Predictors of Cost
The strongest predictors of increased cost in our analysis
were the need for ventricular assist device implantation or
extracorporeal membrane oxygenation. This finding is not
unexpected given that the device, associated equipment,
staffing, and operational costs of these cardiopulmonary
support modalities are significant. In-hospital mortality
was also a strong predictor of increased costs. This finding
was again intuitive in that patients not surviving to
discharge after an operation may have more complex proce-
dures with increased operative times or greater intraopera-
tive resource use, in addition to more complicated
postoperative courses that may involve greater use of con-
sult services and both noninvasive and invasive procedures.
In parallel to our finding, a study of 1221 patients undergo-
ing various cardiac procedures concluded that the highest
costs were in patients with operative mortality, greater
than the costs in patients with nonfatal morbidity or those
with uncomplicated hospital stays.8
We also found that all complications included in our anal-
ysis, with the exception of wound complications, were asso-
ciated with significantly increased costs of care.
Postoperative sepsis was the costliest complication, fol-
lowed by hemorrhage and respiratory tract failure. This
finding is also intuitive in that the management of these spe-
cific complications is resource heavy, including prolonged
intensive care unit stays, increased medication and blood
product use, and additional procedures or reoperations. A
study of Medicare beneficiaries undergoing CABG in
2005 similarly identified septicemia as being associated
with the greatest incremental cost in care and the lengthiest
prolongation of hospitalization of all complications
studied.9ery c January 2014
TABLE 3. Mixed-effect multivariable linear regression analysis for
cost of CABG
Covariates
Coefficient
(95% confidence interval) P value
Fixed-effect parameters
Age (increasing, per y) 64 (71 to 58) <.001
Male sex 564 (448 to 680) <.001
Payment status
Private insurance Reference Reference
Medicare 146 (7 to 284) .04
Medicaid 790 (1040 to 540) <.001
Other 297 (593 to 0) .05
Charlson comorbidity score
0 Reference Reference
1 137 (5 to 280) .06
>2 186 (46 to 327) .009
Urgent or emergent case 693 (575 to 811) <.001
No. of coronary vessels
bypassed
1 Reference Reference
1 622 (466 to 778) <.001
3 1100 (939 to 1261) <.001
>4 1744 (1553 to 1934) <.001
Cardiopulmonary bypass 411 (272 to 551) <.001
Internal mammary artery
not used
1104 (942 to 1267) <.001
Cardiac catheterization
during admission
1399 (1285 to 1513) <.001
Intra-aortic balloon pump 7919 (7736 to 8101) <.001
Permanent pacemaker or
implantable
cardioverter-defibrillator
15,831 (15,440 to 16,221) <.001
Ventricular assist device as
postcardiotomy support
52,094 (50,576 to 53,612) <.001
Extracorporeal membrane
oxygenation
28,999 (25,367 to 32,630) <.001
Coronary angioplasty
during admission
6058 (5697 to 6420) <.001
Non–drug-eluting stent
during admission
3546 (2889 to 4204) <.001
Drug-eluting stent during
admission
6997 (6385 to 7609) <.001
Redo CABG 484 (25 to 942) .04
Teaching hospital 1963 (1405 to 2521) <.001
Hospital region
South Reference Reference
Midwest 3505 (1637 to 5372) <.001
West 12,387 (10,294 to 14,480) <.001
Northeast 4907 (2220 to 7593) <.001
Hospital in rural location 5009 (1927 to 8091) .001
Complications
Respiratory failure 3673 (3518 to 3828) <.001
Pneumonia 2020 (1776 to 2265) <.001
Acute renal failure 2417 (2229 to 2605) <.001
Sepsis 11,303 (10,826 to 11,780) <.001
Stroke 1188 (794 to 1581) <.001
Pulmonary embolism 1194 (369 to 2019) .005
(Continued)
TABLE 3. Continued
Covariates
Coefficient
(95% confidence interval) P value
Gastrointestinal tract
bleed
1153 (416 to 1890) .002
Wound complication 65 (336 to 466) .75
Hemorrhage 5260 (5028 to 5491) <.001
Cardiac shock or arrest 523 (358 to 688) <.001
Annual hospital CABG
volume (decreasing, per
100 cases)
768 (399 to 1134) <.001
Length of hospitalization
(increasing, per d)
2428 (2419 to 2437) <.001
In-hospital mortality 16,758 (16,391 to 17,125) <.001
Year of operation (more
recent, per y)
227 (297 to 156) <.001
Random-effect parameter
Individual hospital effect 9560 (9035 to 10,117) <.001
CABG, Coronary artery bypass grafting.
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DA higher comorbidity burden, more bypassed vessels,
redo operation, and use of intra-aortic balloon pump also
increased the cost of CABG in our analysis. These factors
have been shown in prior studies to correlate with worse
clinical outcomes and increased resource use.7,8,10 Not
unexpectedly, longer hospital stays also correlated with
greater costs in our multivariable model. We found that
decreasing hospital CABG volume was associated with
higher patient-level costs, a finding that has been demon-
strated in a prior statewide analysis of isolated CABGs.11
Interestingly, this association was independent of patient
characteristics and clinical outcomes in our model, suggest-
ing that the cost savings at higher-volume institutions are
not entirely explained by reductions in operative mortality
or morbidity.
In addition, the use of cardiopulmonary bypass was asso-
ciated with increased inpatient costs in the multivariable
model. Off-pump CABG has been shown in prior studies
to be associated with lower costs compared with on-pump
CABG.12,13 Same admission cardiac catheterization,
coronary angioplasty, and coronary stent placement were
each associated with increased costs, presumably because
of the additive costs of the procedures themselves, in
addition to potentially higher risks of acute kidney injury
and increased CABG complexity or mortality risk.10,14,15
Limitations
A major limitation of our study is that we were unable to
itemize the specific costs of care because these were not
available in the registry. Moreover, identifying the differ-
ences between hospitals with respect to individual compo-
nents of overall cost, such as operating room costs,
medication costs, or costs related to postoperative tests or
procedures, may help shed more insight into the reasons
for such wide variability among institutions. Although werdiovascular Surgery c Volume 147, Number 1 113
FIGURE 2. Forest plot depicting the results of the mixed-effect linear regression model for cost of coronary artery bypass grafting (CABG).
AICD, Automated implantable cardioverter defibrillator.
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for Healthcare Research and Quality for each individual
hospital, accurately assessing true costs is challenging and
susceptible to accounting-related and other errors. In addi-
tion, there may be other clinical factors not included in the
Nationwide Inpatient Sample that affect costs but were un-
able to be accounted for in our multivariable model.
Another important limitation was that early readmissions
after discharge and their associated costs were not included
in this analysis. Although controversial, it is conceivable
that hospitals with fast-track pathways for early discharge
after CABG may have lower costs during that particular
admission, but this may come at the expense of higher read-
mission rates.16,17 Capturing these patients would be
important to gain a sense of the true overall costs of
CABG. We also did not include longer-term costs related
to patients requiring outpatient nursing or being discharged
to facilities that provide extended care. These factors
contribute to the overall cost of CABG but were not avail-
able for inclusion in our analysis.17,18
Finally, theNationwide Inpatient Sample is an administra-
tive database and there are limitations in conducting analyses
using clinical parameters with such databases. In comparing
our study population characteristics with those presented in
an analysis of isolated CABGs from the Society of Thoracic114 The Journal of Thoracic and Cardiovascular SurgSurgeons’ Database, the use of the internal mammary artery
was lower and the use of off-pump CABG was higher in our
data.19 The proportion of cases performed on an urgent or
emergent basis or requiring a preoperative intra-aortic
balloon pump was similar. Although the discrepancies may
be the result of differences between hospitals participating
in the Society of Thoracic Surgeons Database and nation-
wide practice patterns, it may also be because of differences
between administrative and clinical registries.CONCLUSIONS
This study of more than 180,000 patients at 633 hospitals
in the United States demonstrates a substantial degree of
variability in costs of CABG between institutions.We deter-
mined that individual hospital centers, independent of mul-
tiple patient- and outcome-specific factors, are drivers of
these differences. Comparison of hospital-specific behavior
with identification of the causes of cost discrepancies repre-
sents an opportunity for standardization of care and
improvement in resource use.References
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Dr T. Bruce Ferguson (Greenville, NC). I would like to
congratulate Dr Kilic and his coauthors on an important study
using the National Inpatient Sample. This is something that we
have started doing more and more frequently, and this is an elegant
analysis using that rich data resource. As well, the findings of your
study are actually provocative in supporting something we have
suspected for some time, while also introducing some new
thoughts into the equation.The Journal of Thoracic and CaYou indicated in your paper and in the presentation that 30% of
the overall variability in cost is driven by the nature of the environ-
ment in which the services are delivered. You conclude that the
variability, by any criteria, is excessively high. This is a health pol-
icy issue that CMS would look at and say variability is bad, and we
need to figure out why.
The other part of your interesting data, however, focused on in-
hospital issues related to mortality, including sepsis and some
things we normally would not think of as necessarily driving
health care costs in coronary bypass surgery. It is not surprising
to me that the VAD patients and the ECMO patients generated
the highest costs, but, fortunately, they occur infrequently.
So, I have 2 questions for you, 1 in each area.
At the health policy level, if we as stewards of our specialty can
look and see that there is this huge variability in the cost of coro-
nary bypass surgery across this sampling of hospitals across the
country, what can we do at the specialty level that would generate
information at the health policy level that would reduce that level
of the variation and excess in health care costs?
And the second question is, in terms of the in-hospital mortal-
ity and the single greatest cause of morbidity, which is sepsis,
what could we do at the local level to be able to drive those costs
down? Can we fix sepsis by putting central lines in safely and
preventing pneumonia and doing MRSA screening and so forth?
Do we really think about reducing health care costs when we do
these things? And is there a point at which we say to a patient
who is going to die and their family, I am sorry, we cannot
really do anything else? Particularly when this occurs so
infrequently?
Your study is provocative in raising these 2 important issues.
Dr Kilic. Thank you, Dr Ferguson, for those comments and
questions. To address your first question about health policy impli-
cations, I think what this study does is really serves as a platform to
demonstrate statistically that there is a significant variability be-
tween institutions with respect to costs of CABG. The future steps
will be to identify specifically what processes of care are different
between those institutions, because what these data identify is that
there may be a comparable quality of care in terms of hard data,
such as mortality and morbidity, between institutions, but the path-
ways that are used to achieve that level of care are significantly
different, with significantly differing costs. So, what this does is
really just serves as a platform, and we need to do more investiga-
tion to figure out what the specific processes are that are contrib-
uting to these differing costs.
With respect to your second question about sepsis and mortal-
ity, again, when we are talking about evaluating providers or
evaluating programs, the gold standard should be the outcomes
and not surrogates for outcomes such as costs. So, I think the ul-
timate responsibility should be to provide good quality of care
with low mortality and low morbidity, and these data sort of
expectedly show that sepsis, which is going to result in prolonged
ICU stays and greater resource utilization, is a significant driver
of cost. That is not to say that we would not potentially be able to
look at how different institutions manage sepsis, their adherence
to clinical guidelines, to see if there is some type of divergence in
how those specific complications are managed to see if that may
be contributing to the differing costs as well, and I think the same
things apply for the in-hospital mortality.rdiovascular Surgery c Volume 147, Number 1 115
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DDr Ferguson. One of the implications of your data and study
in the health care environment, which is evolving in the United
States, is that providers are only going to get paid for better
quality care and lower-cost care. So, addressing both of those
issues is going to become important if we are going to reduce
the 30% variability across the providers; the alternative is
that there will be many fewer places doing coronary bypass
surgery.
Nice paper, and my congratulations to the authors.
Dr Kilic. Thank you.
Dr George Magovern (Pittsburgh, Pa). Would you further
define how you determined cost? Is cost a function of the charges
that a hospital agrees to or are they actual costs of the procedure?
Dr Kilic. Thank you for that question. The Nationwide Inpa-
tient Sample will actually provide the charges in the data set, and
the AHRQ has specific costtocharge ratios that they develop for
each individual hospital. So, utilizing that ratio, we are able
to derive actual costs, which we believe are a better reflection
of actual resource utilization versus the charges, which can
affect payer policies and other things not related to resource
utilization.
Dr Magovern. My second question is that as you decrease the
cost and increase the efficiency of coronary bypass surgery and
move it out into smaller hospitals, you also then make it more diffi-
cult to innovate or improve upon an operation. Specifically, how
will small-volume centers learn to do off-pump coronary surgery
or robotic coronary procedures?
In conclusion, most operative procedures evolve over time.
Thus, surgeons need to find a balance between lowering costs
and decreasing variability on one hand and improving outcomes116 The Journal of Thoracic and Cardiovascular Surgwith improvements in the operation with minimally invasive tech-
niques, robotics, etc.
Dr Kilic. That is an excellent point.
Dr Claudio Muneretto (Brescia, Italy). I congratulate the
authors for a nice paper. I did not find atrial fibrillation as a risk
factor for increasing cost. Many previous studies demonstrate
that atrial fibrillation made longer the stay in the hospital, made
higher the consultant cost for several physicians, and, in addition,
increases significantly stroke rate, renal failure, and low cardiac
syndrome. Could you comment on that?
Dr Kilic. That is a great question regarding atrial fibrillation
and why that was not depicted as a predictor of cost. We actually
did not include the individual diagnostic comorbidities in the
mixed-effect linear regression model. Instead, what we utilized
was the Charlson comorbidity score, which is a cumulative score
that incorporates all those comorbidities into one index. But, I
think it may be a good point to go and look back at the specific co-
morbidities and see which ones tend to be the drivers of cost.
Dr A. Pieter Kappetein (Rotterdam, The Netherlands). Thank
you much. Excellent paper. My question is also related to the
previous issue. Why did you use the Charlson comorbidity index
and not, for example, the STS score? Are there certain advantages
or disadvantages to one of these scores?
Dr Kilic. Ideally, we would like to use something like the STS
score. Unfortunately, many of those variables that are in the STS
CABG riskmodel are not available in the NIS registry. So, it would
just simply be a limitation of the database. But, again, I do think it
would be worth going back and looking at the specific comorbid-
ities and see if there are individual ones that seem to drive costs
more than the others.ery c January 2014
